Ulcerative Colitis

Ulcerative Colitis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJMRA1102942
P698PubMed publication ID22047562

P50authorSilvio DaneseQ89573798
P2093author name stringClaudio Fiocchi
P433issue18
P407language of work or nameEnglishQ1860
P921main subjectcolitisQ2453464
P304page(s)1713-1725
P577publication date2011-11-03
P1433published inThe New England Journal of MedicineQ582728
P1476titleUlcerative Colitis
P478volume365

Reverse relations

cites work (P2860)
Q895117475-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis
Q35022882A 3D Polymer Model for Future Nutrition Design Novel Nutrition Approach for Cystic Fibrosis, Ulcerative Colitis and Crohn's Disease
Q60047624A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation
Q54933580A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease.
Q36283368A Novel Peroxisome Proliferator-activated Receptor (PPAR)γ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in Colitis
Q42365590A Novel Role of Spred2 in the Colonic Epithelial Cell Homeostasis and Inflammation.
Q38605223A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients with Ulcerative Colitis-associated Colorectal Cancer.
Q92446581A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis
Q53362870A Role for MYC in Lithium-Stimulated Repair of the Colonic Epithelium After DSS-Induced Damage in Mice.
Q35973766A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease
Q64997138A diet including xanthan gum triggers a pro-inflammatory response in Wistar rats inoculated with Walker 256 cells.
Q36179468A gastroenterologist's guide to probiotics
Q35238316A probabilistic model to predict clinical phenotypic traits from genome sequencing
Q92525985A product review of vedolizumab in inflammatory bowel disease
Q47387828A refined and translationally relevant model of chronic DSS colitis in BALB/c mice
Q39023867A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010.
Q35169255A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research
Q38812824A systematic review of the role of DNA methylation on inflammatory genes in ulcerative colitis
Q64106175ADP-ribosylation signalling and human disease
Q27028024Achieving the best bowel preparation for colonoscopy
Q47102876Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases
Q36890647Acute blockade of IL-25 in a colitis associated colon cancer model leads to increased tumor burden
Q38098468Adalimumab: a review of its use in the treatment of patients with ulcerative colitis
Q34101549Alterations in the gut microbiome of children with severe ulcerative colitis
Q35767401Altered Fecal Microbiota in Paediatric Inflammatory Bowel Disease
Q58719404Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Rats by Keap1/Nrf-2 Activation, Intestinal Barrier Function, and Gut Microbiota Regulation
Q51544073Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.
Q28079322An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
Q64956401Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
Q37110983Andrographolide derivative AL-1 ameliorates TNBS-induced colitis in mice: involvement of NF-кB and PPAR-γ signaling pathways
Q38816194Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future.
Q24187593Anti-MAdCAM antibody for induction of remission in ulcerative colitis
Q38731835Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells
Q46236112Anti-inflammatory, antioxidant and anti-apoptotic activity of diosmin in acetic acid-induced ulcerative colitis
Q90390539Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis
Q89572940Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients
Q37176942Association between Helicobacter Pylori infection and ulcerative colitis--a case control study from China
Q34346345Association of the interleukin-22 genetic polymorphisms with ulcerative colitis
Q90735821Associations between an MDM2 gene polymorphism and ulcerative colitis by ARMS-PCR
Q37086842Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis
Q92238029Berberine Protects Mice Against Dextran Sulfate Sodium-Induced Colitis by Activating mTORC1 Pathway
Q51035866Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease.
Q38262662Biological therapy for ulcerative colitis
Q40078937Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting.
Q38978344Biosimilars in IBD: from theory to practice
Q38210630Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target
Q35826470Bone marrow-derived mesenchymal stem cell transplantation ameliorates oxidative stress and restores intestinal mucosal permeability in chemically induced colitis in mice
Q34474024Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis
Q35905213CD101 inhibits the expansion of colitogenic T cells.
Q56889158CD69 enhances immunosuppressive function of regulatory T-cells and attenuates colitis by prompting IL-10 production
Q55504526Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoids.
Q42589189Carbohydrate Elimination or Adaptation Diet for Symptoms of Intestinal Discomfort in IBD: Rationales for "Gibsons' Conundrum".
Q50966061Chemically induced mouse models of acute and chronic intestinal inflammation.
Q41194978Chlorogenic Acid Ameliorates Experimental Colitis by Promoting Growth of Akkermansia in Mice
Q35655815Chromosome-associated protein D3 promotes bacterial clearance in human intestinal epithelial cells by repressing expression of amino acid transporters
Q53122367Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.
Q37387994Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis
Q55424510Clinical Implication of Enlarged Prostate in Patients with the Ileal Pouch-anal Anastomosis for Inflammatory Bowel Disease.
Q33865208Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Q90656651Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis
Q57065900Colonoscopic-guided pinch biopsies in mice: A useful model for evaluating the roles of host and luminal factors in colonic inflammation
Q91764358Combined Signature of the Fecal Microbiome and Plasma Metabolome in Patients with Ulcerative Colitis
Q97905242Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients
Q47745759Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis.
Q53692282Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis.
Q45083617Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients.
Q36530664Complete resolution of non-necrotizing lung granuloma and pyoderma gangrenosum after restorative proctocolectomy in a woman with severe ulcerative colitis and cytomegalovirus infection.
Q58764428Comprehensive analysis identifying aberrant DNA methylation in rectal mucosa from ulcerative colitis patients with neoplasia
Q64055217Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review
Q41912959Correlation of CCL20 expression in rectal mucosa with the development of ulcerative colitis-associated neoplasia
Q90270023Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Q39078228Crosstalk between intestinal epithelial cell and adaptive immune cell in intestinal mucosal immunity.
Q38671272Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease
Q38763559Current and emerging therapeutic targets for IBD.
Q40500478Cutaneous manifestations in inflammatory bowel disease: a single institutional study of non-neoplastic biopsies over 13 years
Q39206254Cytokines in inflammatory bowel disease
Q28080901Cytokines, IBD, and colitis-associated cancer
Q38850512Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease.
Q28083490Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review)
Q42223966Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity?
Q64097623Denitrase activity of reduces the oxidized compound 3-nitrotyrosine in mice liver with colitis
Q28066449Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis
Q35209892Diet, microbiota, and inflammatory bowel disease: lessons from Japanese foods.
Q64091062Dietary Protein Intake Level Modulates Mucosal Healing and Mucosa-Adherent Microbiota in Mouse Model of Colitis
Q91723286Dietary destabilisation of the balance between the microbiota and the colonic mucus barrier
Q39167818Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC.
Q42293551Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study
Q34075201Distinct kinetics in the frequency of peripheral CD4+ T cells in patients with ulcerative colitis experiencing a flare during treatment with mesalazine or with a herbal preparation of myrrh, chamomile, and coffee charcoal
Q47583468Do patients living with ulcerative colitis adhere to healthy eating guidelines? A cross-sectional study
Q28075218Dysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease
Q37194925ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells
Q47857757Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.
Q41826640Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis
Q49500932Effect of roxithromycin on mucosal damage, oxidative stress and pro-inflammatory markers in experimental model of colitis
Q37633139Effects of Herb-Partitioned Moxibustion on the miRNA Expression Profiles in Colon from Rats with DSS-Induced Ulcerative Colitis
Q42097592Effects of Rhizophora mangle on Experimental Colitis Induced by TNBS in Rats
Q28553419Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis
Q28084236Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis
Q64227685Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials
Q49948526Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis
Q48329328Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis
Q36637710Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience
Q54335763Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis.
Q42375646Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
Q39306383Emerging treatments for ulcerative colitis: a systematic review.
Q54273411Endoscopic finding of spontaneous hemorrhage correlates with tumor necrosis factor alpha expression in colonic mucosa of patients with ulcerative colitis.
Q26799615Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections
Q39367550Epidemiological and clinical aspects of ulcerative colitis in west of Iran: a cross sectional study
Q37578610Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt
Q37992592Epigenetics: Concepts and relevance to IBD pathogenesis
Q26853555Epigenetics: the fine-tuner in inflammatory bowel disease?
Q27321681Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis
Q35169275Etiopathogenesis of chronic inflammatory bowel diseases. Role of the immune system
Q24186788Etrolizumab for induction of remission in ulcerative colitis
Q24187269Etrolizumab for induction of remission in ulcerative colitis
Q26801531Evaluating the Oxidative Stress in Inflammation: Role of Melatonin
Q50613311Evaluation of cardiac function by two-dimensional speckle tracking echocardiography in ulcerative colitis patients.
Q42872380Evidence against a systemic arterial defect in patients with inflammatory bowel disease
Q37192429Expression Profile of p53 and p21 in Large Bowel Mucosa as Biomarkers of Inflammatory-Related Carcinogenesis in Ulcerative Colitis
Q34437894Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis
Q39852944Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan
Q57184720Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
Q36050474Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis
Q40236724Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis
Q33726429Fibroblast Growth Factor 21 Deficiency Attenuates Experimental Colitis-Induced Adipose Tissue Lipolysis
Q26747341Fibroblasts, an inconspicuous but essential player in colon cancer development and progression
Q42630337Forced treadmill exercise training exacerbates inflammation and causes mortality while voluntary wheel training is protective in a mouse model of colitis
Q30844786Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
Q36006136Frequency and risk factors of primary sclerosing cholangitis among patients with inflammatory bowel disease in North-East of Iran
Q38619050From Genes to Mechanisms: The Expanding Spectrum of Monogenic Disorders Associated with Inflammatory Bowel Disease
Q52547514GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis.
Q52353649Galectins in Intestinal Inflammation: Galectin-1 Expression Delineates Response to Treatment in Celiac Disease Patients.
Q33781693Gene-gene and gene-environment interactions in ulcerative colitis.
Q37217063Genetic mapping with multiple levels of phenotypic information reveals determinants of lymphocyte glucocorticoid sensitivity
Q38794312Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.
Q26866110Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications
Q28236322Golimumab for the treatment of ulcerative colitis
Q38218081Golimumab in unresponsive ulcerative colitis
Q35990398Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I.
Q38756562Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications
Q27021781Gut-central nervous system axis is a target for nutritional therapies
Q38836219Health utility of patients with Crohn's disease and ulcerative colitis: a systematic review and meta-analysis
Q33867430Helminths in the gastrointestinal tract as modulators of immunity and pathology.
Q38574126Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes
Q92860876Hippocampal neural stem cells and microglia response to experimental inflammatory bowel disease (IBD)
Q38896538How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease.
Q47266007Human filarial proteins attenuate chronic colitis in an experimental mouse model.
Q38082620Hydroxylases as therapeutic targets in inflammatory bowel disease.
Q92786954IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease
Q43783161IL-9 and its receptor are predominantly involved in the pathogenesis of UC.
Q58108127IL-9 promotes the pathogenesis of ulcerative colitis through STAT3/SOCS3 signaling
Q34568290IRGM variants and susceptibility to inflammatory bowel disease in the German population
Q40480972Identification of a human intestinal myeloid cell subset that regulates gut homeostasis.
Q50042967Immunological pathogenesis of inflammatory bowel disease
Q38060831Immunosuppressive and biologic therapy for ulcerative colitis.
Q38623451Impact of esophagogastroduodenoscopy and ileocolonoscopy on diagnosis and therapy in patients with rheumatic diseases-a retrospective cohort study
Q33768802Impact of serum-derived bovine immunoglobulin/protein isolate therapy on irritable bowel syndrome and inflammatory bowel disease: a survey of patient perspective
Q90656470Impact of therapies on bowel damage in Crohn's disease
Q48259906Impaired resolution of DSS-induced colitis in mice lacking the glucocorticoid receptor in myeloid cells.
Q35178414Impaired self-renewal and increased colitis and dysplastic lesions in colonic mucosa of AKR1B8-deficient mice
Q55512056Improving IBD Care: A Personalized Approach to Management.
Q46383363Increased Proliferation of the Pancreatic Duct Gland Compartment in Type 1 Diabetes
Q59813626Increased Risk of Ulcerative Colitis in Patients with Periodontal Disease: A Nationwide Population-Based Cohort Study
Q38830085Indole compounds may be promising medicines for ulcerative colitis.
Q53146956Induced genome maintenance pathways in pre-cancer tissues describe an anti-cancer barrier in tumor development.
Q93603852Inflammatory bowel disease
Q35012080Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil
Q39010059Inflammatory bowel disease: Traditional knowledge holds the seeds for the future
Q27690759Inflammatory bowel disease: an increased risk factor for neurologic complications
Q45269185Inflammatory bowel diseases and psychological issues: A new approach for a systematic analysis of the academic debate
Q27005445Inflammatory pathways of importance for management of inflammatory bowel disease
Q26765847Innate Sensing of the Gut Microbiota: Modulation of Inflammatory and Autoimmune Diseases
Q34784772Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis
Q26764757Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer
Q36715515Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity
Q41024376Intestinal anti-inflammatory activity of Ground Cherry (Physalis angulata L.) standardized CO2 phytopharmaceutical preparation.
Q40420311Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms.
Q38217832Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?
Q26865446Janus kinase inhibitors in autoimmune diseases
Q28539860Job strain and the risk of inflammatory bowel diseases: individual-participant meta-analysis of 95,000 men and women
Q40067106Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach.
Q38125275Keeping the bowel regular: the emerging role of Treg as a therapeutic target in inflammatory bowel disease.
Q37402440L13a-dependent translational control in macrophages limits the pathogenesis of colitis
Q31143812Lineage-specific expression of bestrophin-2 and bestrophin-4 in human intestinal epithelial cells
Q47673905Loss of acid ceramidase in myeloid cells suppresses intestinal neutrophil recruitment.
Q90092673Lovastatin derivative dehydrolovastatin ameliorates ulcerative colitis in mice by suppressing NF-κB and inflammatory cytokine expression
Q40966135Low-frequency ultrasound for drug delivery in the gastrointestinal tract
Q38840924MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation.
Q38635974Management of inflammatory bowel disease with Clostridium difficile infection
Q36212191Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin
Q33819473Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease
Q92097217Materials modulate immunity and gut microbiome
Q57788239Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease
Q47205215Media Consumption and Creation in Attitudes Toward and Knowledge of Inflammatory Bowel Disease: Web-Based Survey.
Q38212225Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates
Q34567518Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database
Q37677012Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage
Q48140849Mesenchymal stromal cells modulate gut inflammation in experimental colitis
Q44607322Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery
Q34821676MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis.
Q92714817MicroRNA-142-5p facilitates the pathogenesis of ulcerative colitis by regulating SOCS1
Q37702348MicroRNA-206 is involved in the pathogenesis of ulcerative colitis via regulation of adenosine A3 receptor
Q36096047MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice
Q27025092MicroRNAs in inflammatory bowel disease--pathogenesis, diagnostics and therapeutics
Q35112183Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist
Q47215602Microbiota dysbiosis in inflammatory bowel diseases: in silico investigation of the oxygen hypothesis
Q26781311Mitochondrial dysfunction in inflammatory bowel disease
Q34385980Mucus and the goblet cell
Q26863622Murine models of inflammatory bowel disease (IBD): challenges of modeling human disease
Q27314871MyD88 mediates the protective effects of probiotics against the arteriolar thrombosis and leukocyte recruitment associated with experimental colitis
Q53075963Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects.
Q92898593Network Pharmacology-Based Investigation into the Mechanisms of Quyushengxin Formula for the Treatment of Ulcerative Colitis
Q38625992New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?
Q64081049New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance
Q35069777New strategies for treatment of inflammatory bowel disease
Q38293802New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease
Q35003977New targets for mucosal healing and therapy in inflammatory bowel diseases
Q40013081Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring
Q33625837Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation.
Q54200104No association between the SOCS-1 -1478CA/del polymorphism and ulcerative colitis in Turkish subjects.
Q38304488Noninvasive evaluation of active pan-ulcerative colitis with multiple strictures using Fluorine-18-Fluorodeoxyglucose positron emission tomography/computed tomography
Q34486064Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function.
Q38161988Novel extended release budesonide formulation for treatment of ulcerative colitis
Q41949151Novel treatment options for ulcerative colitis
Q38831798Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients
Q37600339Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
Q38727510Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis
Q36753873Organizing pneumonia presenting after ulcerative colitis remission.
Q42873201Overexpression of GATA-3 in T cells accelerates dextran sulfate sodium-induced colitis
Q28073745Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer
Q39375417PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue
Q42038488PPARγ in Inflammatory Bowel Disease
Q37626292Palisaded Granulomatous Dermatitis Associated with Ulcerative Colitis: A Comprehensive Literature Review
Q48182579Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.
Q38357630Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis
Q38665573Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders
Q26796432Patient considerations in the management of ulcerative colitis - role of vedolizumab
Q28069324Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions?
Q64262376Personalising medicine in inflammatory bowel disease-current and future perspectives
Q93159935Phospholipid-Based Prodrugs for Colon-Targeted Drug Delivery: Experimental Study and In-Silico Simulations
Q33810986Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis
Q50609014Piroxicam treatment augments bone abnormalities in interleukin-10 knockout mice.
Q36081139Pleomorphic malignant histiocytoma: a rare skin cancer in a patient on azathioprine for ulcerative colitis
Q50426415Positive correlation between disease activity index and matrix metalloproteinases activity in a rat model of colitis.
Q40382305Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients
Q41358364Primary rectal diffuse large B-cell lymphoma associated with ulcerative colitis: a case report
Q40447506Probiotic mixture VSL#3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin-deficient mice.
Q90116607Profiling the lncRNA-miRNA-mRNA ceRNA network to reveal potential crosstalk between inflammatory bowel disease and colorectal cancer
Q45862997Proinflammatory progranulin antibodies in inflammatory bowel diseases
Q38588839Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature
Q50470840Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis.
Q36964100Protective effects of ethanol extract from Portulaca oleracea L on dextran sulphate sodium-induced mice ulcerative colitis involving anti-inflammatory and antioxidant
Q34339382Proteomic analysis of colonic mucosal tissue from tuberculous and ulcerative colitis patients
Q60302490Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review
Q37054120Qingchang Wenzhong Decoction Ameliorates Dextran Sulphate Sodium-Induced Ulcerative Colitis in Rats by Downregulating the IP10/CXCR3 Axis-Mediated Inflammatory Response
Q58787826Radiological Patterns of Lung Involvement in Inflammatory Bowel Disease
Q90325399Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
Q39132618Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease
Q35012024Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation
Q58544445Rectal Lymphoid Follicle Aphthous Lesions Frequently Progress to Ulcerative Colitis with Proximal Extension
Q48119825Regulating the Balance of Th17/Treg via Electroacupuncture and Moxibustion: An Ulcerative Colitis Mice Model Based Study.
Q39662763Regulation of Laminin γ2 Expression by CDX2 in Colonic Epithelial Cells Is Impaired During Active Inflammation
Q37986197Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers
Q47134262Relation between NOD2 genotype and changes in innate signaling in Crohn's disease on mRNA and miRNA levels
Q34575468Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and Transcriptomic [corrected] characterization and correlation to IBD.
Q34813567Relevance of commensal microbiota in the treatment and prevention of inflammatory bowel disease
Q96348665Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial
Q34463139Republished: tracing PAKs from GI inflammation to cancer
Q26747410Resolution of Inflammation: What Controls Its Onset?
Q51191479Restoring Mucosal Barrier Function and Modifying Macrophage Phenotype with an Extracellular Matrix Hydrogel: Potential Therapy for Ulcerative Colitis.
Q42160189Results from a retrospective analysis of colonoscopies for Inflammatory bowel disease and colorectal cancer in a Lebanese tertiary care centre
Q38828436Review article: the pathogenesis of pouchitis
Q40069311Risk factors and clinical implication of superimposed Campylobacter jejuni infection in patients with underlying ulcerative colitis
Q87691389Risk of cardiovascular disease in inflammatory bowel disease
Q50473979Risk of colectomy in patients with ulcerative colitis under thiopurine treatment.
Q90079459Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
Q60920231Role of endoscopy in the surveillance and management of colorectal neoplasia in inflammatory bowel disease
Q26768560Role of regulatory T cell in the pathogenesis of inflammatory bowel disease
Q90341495Roles of Ceramides and Other Sphingolipids in Immune Cell Function and Inflammation
Q54758338Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis?
Q55128199Roseburia intestinalis inhibits interleukin‑17 excretion and promotes regulatory T cells differentiation in colitis.
Q38867779Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis
Q38947390Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
Q37114622Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results
Q98612722Secondary causes of inflammatory bowel diseases
Q38086247Serological markers of inflammatory bowel disease
Q36030169Serum Fatty Acids Are Correlated with Inflammatory Cytokines in Ulcerative Colitis
Q49682864Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis
Q90170171Sesamin Enhances Nrf2-Mediated Protective Defense against Oxidative Stress and Inflammation in Colitis via AKT and ERK Activation
Q41876201Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease
Q38653299Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy
Q39041028Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study
Q36062250Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis
Q37522688Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
Q35121243Shuttling of information between the mucosal and luminal environment drives intestinal homeostasis
Q47209789Simultaneous inference of phenotype-associated genes and relevant tissues from GWAS data via Bayesian integration of multiple tissue-specific gene networks.
Q44390503Skin Manifestations of Inflammatory Bowel Disease
Q39014759Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis
Q92279683Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases
Q42361175Steroid-sparing strategies in the management of ulcerative colitis: efficacy of leukocytapheresis.
Q92635301Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis
Q38214577Surgical Management of Severe Colitis in the Intensive Care Unit
Q38575522Surgical and medical treatment in patients with acute severe ulcerative colitis
Q64264125Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease
Q38222449Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis
Q38837599Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis.
Q47368151Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis
Q92156124Systems Pharmacology and Microbiome Dissection of Shen Ling Bai Zhu San Reveal Multiscale Treatment Strategy for IBD
Q46547713TGF-β Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota.
Q56671802TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells
Q42404774TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration
Q37322789TNF-α Autocrine Feedback Loops in Human Monocytes: The Pro- and Anti-Inflammatory Roles of the TNF-α Receptors Support the Concept of Selective TNFR1 Blockade In Vivo.
Q34508085TNF-α blockade is ineffective in animal models of established polycystic kidney disease
Q89866491TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity
Q37015317Takayasu arteritis associated with ulcerative colitis and optic neuritis: first case in Korea
Q38172801Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy?
Q40882156Technetium-99 m labeling and evaluation of olsalazine: a novel agent for ulcerative colitis imaging
Q35043258Temporal comorbidity of mental disorder and ulcerative colitis
Q39006003Th9 cells in inflammatory bowel diseases
Q46443053The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis
Q64880511The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis.
Q41278499The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial
Q93079402The Effect of Vitamin D on Serum Asymmetric Dimethylarginine in Patients with Mild to Moderate Ulcerative Colitis
Q35897490The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds
Q41473592The Expression of the Short Isoform of Thymic Stromal Lymphopoietin in the Colon Is Regulated by the Nuclear Receptor Peroxisome Proliferator Activated Receptor-Gamma and Is Impaired during Ulcerative Colitis
Q33790179The GTPase-activating protein GIT2 protects against colitis by negatively regulating Toll-like receptor signaling
Q90234037The Gut-Liver Axis in Primary Sclerosing Cholangitis: Are Pathobionts the Missing Link?
Q39077548The Immunological Basis of Inflammatory Bowel Disease
Q87288268The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications
Q47109861The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.
Q35247723The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease
Q38600839The Proteome of Ulcerative Colitis in Colon Biopsies from Adults - Optimized Sample Preparation and Comparison with Healthy Controls
Q57115319The Relationship between Gender, Severity of Disease, Treatment Type, and Employment Outcome in Patients with Inflammatory Bowel Disease in Israel
Q39444977The Risk of Inflammatory Bowel Disease Flares after Fecal Microbiota Transplantation: Systematic Review and Meta-Analysis.
Q55304582The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis.
Q52448502The application of molecular topology for ulcerative colitis drug discovery.
Q26745725The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes
Q40154191The effect of algal polysaccharides laminarin and fucoidan on colonic pathology, cytokine gene expression and Enterobacteriaceae in a dextran sodium sulfate-challenged porcine model.
Q59791119The emerging role of lncRNAs in inflammatory bowel disease
Q37197292The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery
Q35085141The impact of primary and persistent cytomegalovirus infection on the progression of acute colitis in a murine model
Q38996677The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.
Q47884736The role of alpha7 nicotinic acetylcholine receptors in inflammatory bowel disease: involvement of different cellular pathways
Q38820563The role of specialty pharmacy drugs in the management of inflammatory diseases
Q54454921The safety and efficacy of adalimumab in patients with Crohn's disease: the experience of a single Canadian tertiary care centre.
Q26862713The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis
Q42427911The zinc sensing receptor, ZnR/GPR39, triggers metabotropic calcium signalling in colonocytes and regulates occludin recovery in experimental colitis.
Q38950433The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo
Q36522931Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be?
Q38820319Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients
Q47822938Tissue IgG4-positive plasma cells in inflammatory bowel disease: a study of 88 treatment-naive biopsies of inflammatory bowel disease.
Q36759434Tissue-resident dendritic cells and diseases involving dendritic cell malfunction
Q44603472ToF-SIMS and principal component analysis of lipids and amino acids from inflamed and dysplastic human colonic mucosa
Q92628027Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation
Q38401205Tracheal and bronchial involvement in colitis ulcerosa - a colo-bronchitic syndrome? A case report and some additional considerations
Q38210506Tracing PAKs from GI inflammation to cancer.
Q44696806Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
Q37463907Transglutaminase 2 is dispensable but required for the survival of mice in dextran sulfate sodium-induced colitis
Q39172441Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK
Q64254092Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
Q40140168Two Cases of Severe Ulcerative Colitis with Colonic Dilatation Resolved with Tacrolimus Therapy
Q40074887Type 2 immunity in tissue repair and fibrosis
Q39278916Ulcerative Colitis Symptomatology and Depression: The Exacerbator Role of Maladaptive Psychological Processes
Q35781294Ulcerative Colitis: Update on Medical Management
Q35957812Ulcerative colitis presenting as acute infectious gastroenteritis with a paralytic ileus
Q33573189Ulcerative colitis six years after colon cancer: only a coincidence?
Q51032601Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa.
Q51044431Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice.
Q27325548Ultrasound-mediated gastrointestinal drug delivery
Q34030650Update on Janus kinase antagonists in inflammatory bowel disease
Q36144377Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
Q37236388Usefulness of sulfasalazine for patients with refractory-ulcerative colits
Q90293727Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study
Q41289466Utility of CT in the emergency department in patients with ulcerative colitis
Q93108869Validation of US evaluation of ulcerative colitis activity
Q42107239Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis
Q34326912Vedolizumab for Crohn's disease
Q38610119Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Q33996708Xilei san ameliorates experimental colitis in rats by selectively degrading proinflammatory mediators and promoting mucosal repair.
Q90542917siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease
Q94076162siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease

Search more.